License deal in oncolytic virotherapiesOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer … more ➔
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH dealBoehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay … more ➔
Smart bra set to detect breast cancerA French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography. more ➔
GARDP wants five AMR breakers by 2025GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025. more ➔
Sanifit raise €72.2m to push SNF472 developmentSanifit has bagged €72.2m in Spain’s largest private biotech fundraise. more ➔
Genfit in $228m deal with Terns PharmaceuticalsGenfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.   … more ➔
Vesalius Biocapital III Fund closes at €120 millionLife sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m. more ➔
Erytech Pharma SA bags US$57m from SQZ BiotechnologiesErytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies. more ➔
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC studySanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients. more ➔
Karo Pharma acquires Trimb ABKaro Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m). more ➔
